This multisite, prospective, cohort study of patients with MS evaluated patient-reported outcomes, pharmacists' actions, and DMT adherence/persistence. Patients reported low rates of impacted productivity, hospitalization, and relapse due to MS. Pharmacists commonly provided medication education and actions to ensure DMT safety and adherence. Patients had a high rate of adherence (median PDC 88%) and persistence (86% at 12 months). Findings support positive outcomes for HSSP patients.

This study assessed the impact of pharmacist-led tailored monitoring for patients initiating encorafenib and binimetinib combination therapy. Most patients reported at least 1 AE within 14 days of initiating therapy (pre 78%, post 95%). All post-cohort patients received at least 1 pharmacist intervention. Findings support HOPA recommendations for patient follow-up within 14 days of starting a new oral anticancer therapy.

This study assess the impact of pharmacist-led tailored monitoring for patients initiating PARP inhibitor therapy. A retrospective study showed that all patients were able to access medicaiton through the pharmacist-led insurance approval process and 64% of patients required a treatment modification in the first 90 days of therapy. A prospective study reporting the impact of implementing a pharmacist-led targeted monitoring program is forthcoming.

This study compares persistence to HIV PrEP in patients filling their medication through an integrated health-system specialty pharmacy (HSSP) compared to those filling at external pharmacies. These findings demonstrate that patients were better maintained on PrEP therapy when their prescriptions were filled with the HSSP compared to external pharmacies, thus highlighting the role HSSPs can have in ending the HIV epidemic.

This study evaluated patient-reported outcomes in neurology specialty disease states gathered via a monthly refill questionnaire. and corresponding pharmacist interventions. There was a high patient-reported adherence rate at 91%. Most pharmacist interventions focused on ensuring safe and effective medication use. Addressing recent healthcare utilization was the most common intervention.

This study evaluated reasons for nonadherence in a random 10% sample of the patients identified as nonadherent (PDC less than 80%) from the study below. We found that 40% of patients classified as nonadherent were misclassified, with 31% of those due to external fills, and 60% due to provider-recommended gaps in therapy. Most cases of true nonadherence were due to an inability to reach the patient.

This two-part study aimed to identify the rates and reasons of PMN for specialty oral oncolytic agents. In Part I, we used 24 methods to calculate PMN based on combinations of three parameters. In Part II, we reviewed electronic medical records of 198 prescriptions considered PMN by our previous calculation.

This randomized prospective study evaluated the effectiveness pharmacist interventions had on specialty medication adherence using proportion of days covered (PDC). After 8 months post-enrollment, median PDC in the intervention group was significantly higher than the control group. Currently, 3 products related to this research are below:

Patients are recommend to receive all necessary vaccines prior to starting immunosuppressive specialty DMARD therapy. This quality improvement project developed a vaccine screening protocol for patients initiating new specialty medications at an outpatient rheumatology clinic. This protocol was effective in delivering patient-specific vaccine recommendations and was rated as efficient by specialty pharmacists.